This company has been marked as potentially delisted and may not be actively trading. NASDAQ:LOGC LogicBio Therapeutics (LOGC) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestSustainabilityTrendsBuy This Stock About LogicBio Therapeutics Stock (NASDAQ:LOGC) 30 days 90 days 365 days Advanced Chart Get LogicBio Therapeutics alerts:Sign Up Key Stats Today's Range$7.10▼$7.4550-Day Range$2.04▼$2.0752-Week Range$0.26▼$3.77Volume51,711 shsAverage Volume168,718 shsMarket Capitalization$192.11 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview LogicBio Therapeutics, Inc., a genetic medicine company, focuses on developing and commercializing genome editing and gene therapy treatments using its GeneRide and sAAVy platforms. The company's GeneRide technology is a new approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid; and gene delivery platform, sAAVy is an adeno-associated virus, which is designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate is LB-001 that is in Phase I/II clinical trials for the treatment of methylmalonic acidemia. The company has a collaboration with Children's Medical Research Institute to develop next-generation capsids for gene therapy and gene editing applications in the liver, as well as additional tissues; and a collaboration agreement with Takeda Pharmaceutical Company Limited to develop LB-301, an investigational therapy for the treatment of Crigler-Najjar syndrome. The company also has a research collaboration, license, and option agreement with CANbridge Care Pharma Hong Kong Limited; and collaboration agreement with Daiichi Sankyo Company. The company was incorporated in 2014 and is headquartered in Lexington, Massachusetts. Read More LogicBio Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks25th Percentile Overall ScoreLOGC MarketRank™: LogicBio Therapeutics scored higher than 25% of companies evaluated by MarketBeat, and ranked 178th out of 210 stocks in the retail/wholesale sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for LogicBio Therapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of LogicBio Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LogicBio Therapeutics is -1.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLogicBio Therapeutics has a P/B Ratio of 0.82. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.23% of the outstanding shares of LogicBio Therapeutics have been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in LogicBio Therapeutics has recently decreased by 5.99%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLogicBio Therapeutics does not currently pay a dividend.Dividend GrowthLogicBio Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.7 / 5Environmental Score-0.49 Percentage of Shares Shorted4.23% of the outstanding shares of LogicBio Therapeutics have been sold short.Short Interest Ratio / Days to CoverLogicBio Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in LogicBio Therapeutics has recently decreased by 5.99%, indicating that investor sentiment is improving significantly. News and Social Media0.0 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 3 news articles for LogicBio Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 6 people have searched for LOGC on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LogicBio Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 8.10% of the stock of LogicBio Therapeutics is held by insiders.Percentage Held by Institutions46.05% of the stock of LogicBio Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about LogicBio Therapeutics' insider trading history. Receive LOGC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LogicBio Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LOGC Stock News HeadlinesContextLogic Holdings Inc. Reports Second-Quarter 2025 Financial ResultsAugust 7 at 4:10 PM | globenewswire.comContextLogic Holdings Completes Corporate ReorganizationAugust 7 at 6:00 AM | globenewswire.comElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… The "experts" said Elon was finished and Tesla was headed for bankruptcy. Now they're saying the same thing, but Jeff has uncovered Tesla's next breakthrough.August 9 at 2:00 AM | Brownstone Research (Ad)ContextLogic to Announce Second Quarter 2025 Results on August 7, 2025August 4, 2025 | globenewswire.comContextLogic Urges ALL Stockholders to Protect the Value of their Investment by Voting “FOR” the Reorganization TODAYJuly 17, 2025 | globenewswire.comContextLogic Announces Adjournment of Annual Meeting of Stockholders to Allow Additional Time for Stockholders to Vote “FOR” the Reorganization ProposalJuly 10, 2025 | globenewswire.comContextLogic Appoints Finance Executive Michael Scarola as New Chief Financial OfficerJune 25, 2025 | globenewswire.comContextLogic Stock Price, Quotes and Forecasts | NASDAQ:LOGC | BenzingaJune 2, 2025 | benzinga.comSee More Headlines LOGC Stock Analysis - Frequently Asked Questions How were LogicBio Therapeutics' earnings last quarter? LogicBio Therapeutics, Inc. (NASDAQ:LOGC) posted its earnings results on Friday, May, 9th. The company reported ($0.27) EPS for the quarter. LogicBio Therapeutics had a negative trailing twelve-month return on equity of 81.98% and a negative net margin of 141.03%. Read the conference call transcript. When did LogicBio Therapeutics IPO? LogicBio Therapeutics (LOGC) raised $77 million in an initial public offering on Friday, October 19th 2018. The company issued 5,800,000 shares at a price of $12.50-$14.00 per share. Jefferies, Barclays and William Blair acted as the underwriters for the IPO and Chardan was co-manager. Who are LogicBio Therapeutics' major shareholders? Top institutional shareholders of LogicBio Therapeutics include Simplex Trading LLC. View institutional ownership trends. What other stocks do shareholders of LogicBio Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LogicBio Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Ginkgo Bioworks (DNA), Luminar Technologies (LAZR), Toast (TOST) and Globant (GLOB). Company Calendar Last Earnings5/09/2025Today8/09/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorRetail/Wholesale Industry Catalog & mail - order houses Sub-IndustryN/A Current SymbolNASDAQ:LOGC CIK1664106 Webwww.logicbio.com Phone(617) 245-0399FaxN/AEmployees62Year FoundedN/AProfitability EPS (Trailing Twelve Months)($5.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$317 million Net Margins-141.03% Pretax Margin-141.67% Return on Equity-81.98% Return on Assets-52.13% Debt Debt-to-Equity RatioN/A Current Ratio31.60 Quick Ratio31.60 Sales & Book Value Annual Sales$287 million Price / Sales0.67 Cash FlowN/A Price / Cash FlowN/A Book Value$8.96 per share Price / Book0.82Miscellaneous Outstanding Shares26,280,000Free Float24,156,000Market Cap$192.11 million OptionableOptionable Beta2.06 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:LOGC) was last updated on 8/9/2025 by MarketBeat.com Staff From Our PartnersYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LogicBio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share LogicBio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.